Patrick Duxbury > Gowling WLG > London, England > Lawyer Profile
Gowling WLG Offices
4 MORE LONDON RIVERSIDE
LONDON
SE1 2AU
England
- Firm Profile
- Go to...
Patrick Duxbury
Work Department
Intellectual property.
Position
Partner, Head of Life Sciences (UK)
Career
Trained Philip Conn & Co, Manchester; qualified 1993; partner Wragge & Co 1999; Wragge Lawrence Graham & Co, partner, 2014. Regular speaker at conferences and seminars on biotech and pharmaceutical licensing and collaborations; recent member of the Legal Expert network of the Association of British Pharmaceutical Industry. Presenter on the BIO advanced business development course in both the USA and Europe.
Languages
French.
Memberships
Licensing Executives Society; Association of the British Pharmaceutical Industry and the Biotechnology Industry Association.
Education
Queen Elizabeth’s Grammar School; Newcastle University (1989 BSc Hons 2(1)); Chester College of Law (1991 CPE, Distinction; Law Society Finals, First Class Hons).
Leisure
Football, cricket, skiing, walking, family.
Lawyer Rankings
London > Industry focus > Life sciences and healthcare
(Leading individuals)Patrick Duxbury and Robert Breedon lead the practice at Gowling WLG, which is noted for its ‘deep experience‘ in licensing matters and pharmaceutical manufacturing issues. The team regularly assists large pharmaceutical companies such as BioNTech and AstraZeneca, and is known for representing care home and senior facility operators and funders. With his academic background in microbiology and genetics, Duxbury handles an array of transactional issues, including commercialisation deals and collaborations, while Breedon advises both public and private sector clients in the healthcare space on outsourcing contracts and commercial projects.
London > TMT (technology, media and telecoms) > Intellectual property: patents (contentious and non-contentious)
Recommended for its ‘great commercial acumen’, the Gowling WLG IP practice, which is headed by Kate Swaine, has key strengths that include tech patent litigation, SEP/FRAND litigation and work in the life sciences field, to name a few. Alexandra Brodie is noted for her expertise in the technology sector, leading significant cases in the SEP/FRAND sphere, while Paul Inman has considerable experience in pharma patent infringement and revocation actions. Further strengthening the practice is Patrick Duxbury, who is well-versed in handling transactional matters, and Huw Evans, who routinely handles life sciences and technology related matters. Luke Kempton is particularly active in the biotech and pharma sectors, and Jamie Rowlands routinely represents a multitude of clients in global patent disputes, being especially active in the telecoms space. Matt Hervey and Nick Cunningham are also recommended. Jonathan Ball departed to Norton Rose Fulbright in June 2022.
Lawyer Rankings
- Leading individuals London > Industry focus > Life sciences and healthcare
- Intellectual property: patents (contentious and non-contentious) London > TMT (technology, media and telecoms)
- Life sciences and healthcare London > Industry focus
Top Tier Firm Rankings
- Real estate > Property litigation
- Real estate > Property litigation
- Real estate > Environment
- Investment fund formation and management > Listed funds
- Insurance > Insurance: corporate and regulatory
Firm Rankings
- Corporate and commercial > Commercial contracts
- Dispute resolution > Commercial litigation: mid-market
- Real estate > Commercial property: development
- Real estate > Commercial property: investment
- Corporate and commercial > Equity capital markets – small-mid cap
- TMT (technology, media and telecoms) > Intellectual property: patents (contentious and non-contentious)
- TMT (technology, media and telecoms) > Intellectual property: trade marks, copyright and design
- Industry focus > Life sciences and healthcare
- TMT (technology, media and telecoms) > Media: Advertising & marketing
- Employment > Pensions (non-contentious)
- Employment > Pensions: dispute resolution
- Industry focus > Retail and consumer
- Projects, energy and natural resources > Water
- Real estate > Commercial property: corporate occupiers
- Real estate > Construction: contentious
- Real estate > Construction: non-contentious
- Industry focus > Emerging markets
- Corporate and commercial > EU and competition: trade, WTO anti-dumping and customs
- Crime, fraud and licensing > Fraud: civil
- Employment > Health and safety
- Projects, energy and natural resources > Infrastructure: M&A and acquisition financing
- Projects, energy and natural resources > Infrastructure: Project finance and development
- Projects, energy and natural resources > Mining and minerals
- Real estate > Planning
- Projects, energy and natural resources > Power (including electricity, nuclear and renewables)
- Real estate > Property litigation
- Transport > Rail
- Investment fund formation and management > Real estate funds
- Private client > Contentious trusts and probate
- TMT (technology, media and telecoms) > Fintech
- TMT (technology, media and telecoms) > IT and telecoms
- Corporate and commercial > M&A: Lower Mid-Market Deals, £100m-£750m
- Corporate and commercial > Private equity: transactions - mid-market deals (up to £250m)
- Real estate > Property finance
- Real estate > Social housing: finance
- Industry focus > TMT
- Dispute resolution > Banking litigation: investment and retail
- Corporate and commercial > Financial services: contentious
- Corporate and commercial > Venture capital
- Corporate and commercial > EU and competition
- Corporate and commercial > Financial services: non-contentious/regulatory
- Dispute resolution > International arbitration
- TMT (technology, media and telecoms) > Sport